Regulation of the Pax6 : Pax6(5a) mRNA ratio in the developing mammalian brain
BMC Developmental Biology volume 5, Article number: 13 (2005)
Early in mammalian brain development cell proliferation generates a population of progenitor cells whose subsequent divisions produce increasing numbers of postmitotic neurons. Pax6 affects both processes and it has been suggested that this changing role is due at least in part to changes in the relative concentrations of its two main isoforms, (i) Pax6 and (ii) Pax6(5a), created by insertion of a 42 bp exon (exon 5a) into one of the two DNA-binding domains. Crucially, however, no previous study has determined whether the ratio between Pax6 and Pax6(5a) transcripts alters during mammalian neurogenesis in vivo.
Using RNase protection assays, we show that Pax6 transcripts are 6–10 times more prevalent than Pax6(5a) transcripts early in neurogenesis in the murine telencephalon, diencephalon and hindbrain and that the ratio later falls significantly to about 3:1 in these regions.
These changes in vivo are similar in magnitude to those shown previously to alter target gene activity in vitro and might, therefore, allow the single mammalian Pax6 gene to carry out different functions at different times in mammalian brain development.
Pax6 is expressed in the developing eye and brain, where it affects both progenitor cell production and neuronal differentiation [1–5]. The Pax6 protein contains two DNA binding domains, a paired domain (PD) and a paired-type homeodomain (HD) (Fig. 1A). The PD consists of two separate helix-turn-helix motifs, termed PAI and RED, which act on different target sequences . The best characterised Pax6 alternative splicing event, involving the insertion of a 42 bp exon (exon 5a) into the PAI subdomain of the PD, results in two major Pax6 isoforms [Pax6 and Pax6(5a)] with different DNA-binding properties. In vitro studies have shown that the PAI subdomain of Pax6 binds preferentially to a consensus sequence (P6CON)  but that PAI subdomain disruption in Pax6(5a) allows the RED subdomain to bind an alternative sequence (5aCON) .
Pax6 affects early progenitor cell proliferation and later neuronal differentiation in the developing brain [4, 5]. This changing role might be due at least in part to a shift in the relative concentrations of Pax6 and Pax6(5a) during development but there has been no previous report of such alterations during neurogenesis in the brain in vivo. We anticipated that even relatively small changes in the Pax6 : Pax6(5a) ratio might be important since stronger effects on gene activity via P6CON and 5aCON are observed if Pax6 and Pax6(5a) are introduced into cultured cell lines at ratios of 1:1 or 8:1 than at ratios of 2:1, 4:1 or 16:1 . We selected a direct method for quantification of the ratio (RNase protection assays) and carried out multiple assays so as to obtain statistically analysable data on key Pax6-expressing brain tissues at a range of ages throughout neurogenesis. We found changes in the ratio similar in magnitude to those shown previously to alter target gene activity in vitro.
Results and Discussion
RNase protection assays were carried out on tissues dissected from wild type mouse embryos aged E12.5-E18.5 and quantified by densitometry (Fig. 1). The Pax6 : Pax6(5a) ratio varied throughout neurogenesis in the telencephalon, diencephalon and hindbrain, following a similar pattern in each (Table 1). In the telencephalon, the ratio was about 6:1 early in neurogenesis, at E12.5, but was significantly lower (about 2:1) at each subsequent age (p < 0.05–p < 0.01; Table 1). In the diencephalon and hindbrain, ratios were about 8:1 and 10:1 at E12.5 but were lower (about 2:1 to 4:1) from E14.5-E18.5 (Table 1); these decreases were statistically significant when data from all three age groups were combined (p < 0.05 for both tissues). Combining results from the telencephalon, diencephalon and hindbrain showed a significant fall in the Pax6 : Pax6(5a) ratio between E12.5 and E14.5, from approximately 8:1 to 3:1 (p < 0.05), with a further slight decrease at E16.5 and E18.5 (p < 0.01; Table 1). Data on the Pax6 : Pax6(5a) ratio in the eye at E12.5-E18.5 did not show the same trend (Table 1). Ratios varied from about 10:1 at E14.5 to about 4:1 at E18.5 but none of the differences were statistically significant. Although we did not detect significant changes in the eye, it is possible that non-synchronised changes in the ratio do occur within its component Pax6-expressing neural and non-neural tissues (cornea, lens and retina). Neither Pax6 nor Pax6(5a) was detected in samples from the feet.
There is evidence that Pax6 and Pax6(5a) have different functions in vivo in both vertebrates [9–11] and invertebrates [12, 13]. Studies of Pax6- and Pax6(5a)-related genes in Drosophila melanogaster, ey/ toy and eyg/ toe, have shown that they promote, respectively, differentiation and proliferation of eye precursor cells [12, 13]. Overexpression of Pax6 and Pax6(5a) can alter the expression of different sets of genes in mammals [10, 11]. Mammalian brain cells reduce their proliferation in response to overexpression of Pax6 or Pax6(5a) and increase their neurogenesis in response to overexpression of Pax6 . It is possible that a reduction in the Pax6 : Pax6(5a) mRNA ratio from E14.5 is involved in programming progenitor cells to initiate processes that occur later in embryogenesis. Such processes are potentially numerous; they might, for example, include the transition from predominantly neurogenesis to the major phase of gliogenesis or the development of specific sets of later-generated neurones such as the superficial layers of the cerebral cortex.
We conclude that the Pax6 : Pax6(5a) ratio falls in the telencephalon, diencephalon and hindbrain during neurogenesis and, moreover, the magnitude of the change is in the range that alters target gene expression in vitro . This finding allows the possibility that changes in the relative expression levels of isoforms of a single Pax6 gene might result in changes in the functions of this gene in mammalian brain development.
For each RNase protection assay, wild-type mice (CD-1) were time-mated [the day of conception was designated embryonic day 0.5 (E0.5)] and killed on E12.5, E14.5, E16.5 or E18.5. The telencephalon, diencephalon, hindbrain, eyes and feet (used as a Pax6 non-expressing control tissue) were dissected from each embryo. Tissues from multiple embryos were combined so as to obtain sufficient material for each assay. Total RNA was isolated from tissue snap-frozen in liquid nitrogen, its integrity was checked by agarose gel electrophoresis and its concentration was measured using a fluorimeter. The riboprobe was designed to span the Pax6 mRNA from exon 3 to exon 5a so as to protect Pax6 and Pax6(5a) mRNAs (Fig. 1A). Oligonucleotides 5'-AAG TGG ACG TAT ATC CCA GTT CTC-3' and 5'-AGC ACC TGG ACT TTT GCA TC-3' were used to amplify sequence from mouse Pax6 cDNA. Pax6 cDNA was cloned into pCR-BluntII-TOPO and sequenced across the Pax6 insert in both directions to identify clones with Pax6 sequence in the appropriate orientation to generate antisense probe. The plasmid pTRI-GAPDH (Ambion) was used for synthesis of a murine glyceraldehyde-3-phosphate dehydrogenase (GAPDH) riboprobe. Riboprobe synthesis was carried out using the Maxiscript SP6 in vitro transcription kit (Ambion) in the presence of 40 μCi α-32P-UTP 800 Ci/mmol (Amersham). Riboprobes were purified using a MicroSpin G25 column (Amersham Biosciences).
RNase protection assays were performed on 1 μg total RNA from E12.5 and E14.5 embryonic tissues, or 4 μg total RNA from E16.5 and E18.5 embryonic tissues, using the Hyb Speed kit (Ambion). The quality the undigested full-length riboprobe was examined and that of all total RNA samples was assessed using a GAPDH riboprobe (e.g. Fig. 1B). Products were resolved on 6% polyacrylamide, 8 M urea gels that were then fixed (15% methanol, 5% acetic acid for 30 minutes), dried and exposed to film with an intensifying screen. Where GAPDH signal was weak, this was a sign that protein or DNA contamination had led to inaccurate RNA quantification, and these samples were excluded from subsequent analyses. Gel bands were quantitated using a GS-710 densitometer and the Quantity One software package (BioRad: background subtraction was performed using the rolling disk method ; Fig. 1C). Each assay was repeated several times (n values for the number of assays for each tissue at each age are in Table 1).
Walther C, Gruss P: Pax-6, a murine paired box gene, is expressed in the developing CNS. Development. 1991, 113: 1435-1449.
Hill RE, Favor J, Hogan BL, Ton CC, Saunders GF, Hanson IM, Prosser J, Jordan T, Hastie ND, van Heyningen V: Mouse small eye results from mutations in a paired-like homeobox-containing gene. Nature. 1991, 354: 522-525. 10.1038/354522a0.
Ton CC, Hirvonen H, Miwa H, Weil MM, Monaghan P, Jordan T, van Heyningen V, Hastie ND, Meijers-Heijboer H, Drechsler M: Positional cloning and characterization of a paired box- and homeobox-containing gene from the aniridia region. Cell. 1991, 67: 1059-1074. 10.1016/0092-8674(91)90284-6.
Heins N, Malatesta P, Cecconi F, Nakafuku M, Tucker KL, Hack MA, Chapouton P, Barde YA, Gotz M: Glial cells generate neurons: the role of the transcription factor Pax6. Nat Neurosci. 2002, 5: 308-315. 10.1038/nn828.
Estivill-Torrus G, Pearson H, van Heyningen V, Price DJ, Rashbass P: Pax6 is required to regulate the cell cycle and the rate of progression from symmetrical to asymmetrical division in mammalian cortical progenitors. Development. 2002, 129: 455-466.
Epstein JA, Glaser T, Cai J, Jepeal L, Walton DS, Maas RL: Two independent and interactive DNA-binding subdomains of the Pax6 paired domain are regulated by alternative splicing. Genes Dev. 1994, 8: 2022-2034.
Epstein J, Cai J, Glaser T, Jepeal L, Maas R: Identification of a Pax paired domain recognition sequence and evidence for DNA-dependent conformational changes. J Biol Chem. 1994, 269: 8355-8361.
Chauhan BK, Yang Y, Cveklova K, Cvekl A: Functional interactions between alternatively spliced forms of Pax6 in crystallin gene regulation and in haploinsufficiency. Nucleic Acids Res. 2004, 32: 1696-1709. 10.1093/nar/gkh334.
Haubst N, Berger J, Radjendirane V, Graw J, Favor J, Saunders GF, Stoykova A, Gotz M: Molecular dissection of Pax6 function: the specific roles of the paired domain and homeodomain in brain development. Development. 2004, 131: 6131-6140. 10.1242/dev.01524.
Chauhan BK, Reed NA, Yang Y, Cermak L, Reneker L, Duncan MK, Cvekl A: A comparative cDNA microarray analysis reveals a spectrum of genes regulated by Pax6 in mouse lens. Genes Cells. 2002, 7: 1267-1283. 10.1046/j.1365-2443.2002.00602.x.
Chauhan BK, Reed NA, Zhang W, Duncan MK, Kilimann MW, Cvekl A: Identification of genes downstream of Pax6 in the mouse lens using cDNA microarrays. J Biol Chem. 2002, 277: 11539-11548. 10.1074/jbc.M110531200.
Dominguez M, Ferres-Marco D, Gutierrez-Avino FJ, Speicher SA, Beneyto M: Growth and specification of the eye are controlled independently by Eyegone and Eyeless in Drosophila melanogaster. Nat Genet . 2004, 36: 31-39. 10.1038/ng1281.
Rodrigues AB, Moses K: Growth and specification: fly Pax6 homologs eyegone and eyeless have distinct functions. Bioessays. 2004, 26: 600-603. 10.1002/bies.20055.
Abe J, Deguchi J, Takuwa Y, Hara K, Ikari Y, Tamura T, Ohno M, Kurokawa K: Tyrosine phosphorylation of platelet derived growth factor beta receptors in coronary artery lesions: implications for vascular remodelling after directional coronary atherectomy and unstable angina pectoris. Heart. 1998, 79: 400-406.
Many thanks to Karen Chapman for advice on RNase protection, and to Tom Pratt and Jane Quinn for help with dissections. This work was funded by the Wellcome Trust.
JP carried out all the RNase protections assays, analysed the results and wrote a first draft of the manuscript. JP, JM, IS and DP all helped conceive and design the study and all worked on and approved the final manuscript.
About this article
Cite this article
Pinson, J., Mason, J.O., Simpson, T.I. et al. Regulation of the Pax6 : Pax6(5a) mRNA ratio in the developing mammalian brain. BMC Dev Biol 5, 13 (2005). https://doi.org/10.1186/1471-213X-5-13